Solid Biosciences Inc. (SLDB) financial statements and ratios from SEC XBRL: revenue $9.90M (TTM), net margin -1760.1%, revenue growth 4.6% YoY. Income statement, balance sheet, cash flow, and valuation. First-party data.
| Revenue (TTM) | $9.90M |
| Net Margin | -1760.1% |
| Revenue Growth (YoY) | 4.6% |
| EPS Growth (YoY) | -35.0% |
| FCF Growth (YoY) | 56.4% |
| Price / Book | 2.39 |
| Price / Sales | 90.25 |
| FCF Yield | -28.2% |
| Altman Z-Score | 2.84 (grey) |
| Sector P/E (Healthcare) | 21.6 |
SLDB overview · SLDB earnings · SLDB KPIs · SLDB investor relations · SLDB ownership · SLDB peers · SLDB filings
Data sourced from U.S. SEC EDGAR XBRL filings. Not personalized investment advice.